Sponsors › GlaxoSmithKline
GlaxoSmithKline
Every GLP‑1 and incretin trial, approval and scheduled result we hold for GlaxoSmithKline, drawn from ClinicalTrials.gov and Drugs@FDA.
GlaxoSmithKline is a commercial sponsor with 26 trials in the incretin class on file here, across 3 molecules. The programme is split between 7 early-stage trials and 19 in phase 3 or later. 8 approved FDA submissions sit against this sponsor in Drugs@FDA.
- Molecules
- albiglutide · exenatide · liraglutide
- Trials on file
- 26
- Active trials
- 0
- Results scheduled
- 0
- Approved FDA submissions
- 8
FDA record
| Date | Drug | Action | Application |
|---|---|---|---|
| 2017-12-20 | albiglutide | Labeling | BLA125431 |
| 2017-12-12 | albiglutide | REMS | BLA125431 |
| 2017-08-01 | albiglutide | Labeling | BLA125431 |
| 2016-09-13 | albiglutide | Labeling | BLA125431 |
| 2015-07-27 | albiglutide | REMS | BLA125431 |
| 2015-05-07 | albiglutide | Labeling | BLA125431 |
| 2015-03-09 | albiglutide | Labeling | BLA125431 |
| 2014-04-15 | albiglutide | Type 1 - New Molecular Entity | BLA125431 |
Trials on file
All 26 incretin trials recorded for this sponsor, active first.